Merck: phase III trial of Keytruda + Lynparza fails

(CercleFinance.com) - Merck announced today that a phase III trial showed that Keytruda combined with chemotherapy followed by Keytruda plus Lynparza in maintenance has failed to meet its two primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of selected patients with metastatic non-squamous non-small cell lung cancer (NSCLC).


The study failed to meet predefined statistical criteria compared with the protocol combining Keytruda and chemotherapy (pemetrexed + carboplatin or cisplatin) followed by Keytruda + maintenance chemotherapy (pemetrexed).

A full evaluation of the data from this study is underway, says the laboratory, which will work with the investigators to share the results with the scientific community.

These results remind us how difficult it can be to treat these patients with metastatic non-squamous non-small cell lung cancer. We sincerely thank the patients and investigators for their important contributions to this study, it commented.


Copyright (c) 2024 CercleFinance.com. All rights reserved.